Elon Musk’s brain chips will soon be tested on volunteers in the UK

Elon Musk’s brain chips reach the UK

Neuralink, Elon Musk’s brain-computer interface company, has launched its first human clinical trial in the UK, expanding beyond the United States for the first time.

This marks a historic step in Europe as the company partners with University College London Hospitals and Newcastle Hospitals.

Seven British patients with severe paralysis will be implanted with the Neuralink chip, giving them the power to operate digital devices using only their thoughts. This move signals a significant milestone for futuristic medicine and Musk’s growing global ambitions.

British patients with paralysis are eligible

Individuals with severe paralysis caused by spinal cord injuries or neurodegenerative diseases like ALS can apply for Neuralink’s UK trial. Candidates must be over 22 years old and have limited or no use of both hands.

This selection ensures the chip is tested on people who could gain the most life-changing benefits. For many, this trial represents a chance to regain a sense of autonomy lost to their condition and to be pioneers in a technology that could redefine mobility and communication.

The chip is smaller than a 10p coin

The N1 chip Neuralink implants into the human brain is about the size of a 10-pence coin, but its implications are massive. It contains 1,000 electrodes across 128 flexible threads that are finer than a human hair.

Once implanted, it can detect brain signals and convert them into digital actions like clicking, scrolling, or typing. Despite its small size, this device represents a monumental leap in how humans interact with machines, shifting control from muscle to mind.

The surgery involves a robot and a neurosurgeon

The procedure to implant the N1 chip is performed with the help of Neuralink’s custom-built R1 surgical robot. The robot’s precision allows it to insert ultra-thin threads into the brain while avoiding damage to blood vessels.

A highly trained neurosurgeon oversees the process, ensuring safety and accuracy. The combination of robotics and human expertise underscores Neuralink’s commitment to safe, scalable brain surgeries.

This robotic precision also enables Neuralink to dream of future clinics performing thousands of such procedures annually.

Neuralink’s goals go beyond restoration

Although Neuralink is currently focused on helping patients with paralysis regain digital control, its long-term ambitions are much broader.

Elon Musk has stated that future applications of the chip could include treating blindness, curing mental health conditions, and even enhancing memory or cognition.

The vision is a future where healthy individuals may choose implants to improve focus, creativity, or productivity. It’s not just about restoring lost abilities, it’s about unlocking new human potential through direct brain-computer communication.

Meet Audrey Crews, a real-life Neuralink user

Audrey Crews, one of the first Neuralink patients in the U.S., was paralyzed from the neck down after a car crash at age 16. After receiving the chip in July 2024, she shared her breakthrough online: she could control a mouse, type, draw, and even attempt her signature again.

“I tried writing my name for the first time in 20 years,” she said. Her story has inspired thousands and demonstrated the real-world power of Neuralink to restore independence through thought alone.

First trials began in the US after FDA approval

After overcoming significant regulatory hurdles, Neuralink launched its first human trials in the U.S. in early 2024. The FDA rejected Neuralink’s 2022 application due to safety concerns, but the company improved both the implant and the surgical robot.

Approval finally came after Neuralink demonstrated that the procedure could be done safely. With several successful U.S. patients implanted, the stage was set for international expansion, starting with the UK.

Noland Arbaugh was the first human patient

In January 2024, Noland Arbaugh became the first person implanted with a Neuralink chip. A 30-year-old quadriplegic from Arizona, Arbaugh quickly became a symbol of Neuralink’s promise.

He used his mind to play video games, write, and interact socially online. Despite 85% of the implant’s threads losing brain contact, Neuralink’s updated software preserved functionality.

Arbaugh’s case proved not only the power of the chip but also Neuralink’s ability to adapt and improve in real time.

The UK is the first European host of Neuralink

The United Kingdom is now the first country in Europe to host Neuralink’s brain chip trials. This marks a significant expansion beyond U.S. borders and opens the door for broader adoption across the continent.

The study has received approval from UK health authorities, including the MHRA and Health Research Authority. This pioneering step advances BCI research and positions the UK as a global hub for neurotechnology innovation.

Up to seven UK participants will be implanted

Neuralink’s UK trial will include seven participants, each selected for their qualifying condition and potential benefit. Surgeries will occur at the National Hospital for Neurology and Neurosurgery, part of University College London Hospitals.

The primary goal is to test the implant’s safety and its ability to allow users to use only their minds with smartphones, computers, and other digital tools. This could lay the groundwork for thousands of future implants across the UK and beyond.

This is part of Neuralink’s global expansion

Neuralink’s UK trial is just one part of a much bigger roadmap. The company has already announced plans for additional trials in Canada and the UAE, and its long-term vision includes dedicated BCI clinics in major cities.

With each international step, Neuralink moves closer to making brain-computer interfaces accessible to millions. The UK trial isn’t just a test; it’s a gateway to global rollout and mass adoption of what Musk calls “telepathic technology.”

Neuralink now offers three core product lines

Neuralink is developing three brain chip solutions. “Telepathy” enables control of devices through thought, aimed at people with paralysis. “Blindsight” is intended to restore vision in the blind. And “Deep” focuses on neurological disorders like tremors and Parkinson’s disease.

These diverse applications show that Neuralink is aiming not just to improve accessibility but to enter mainstream neuromedicine. Each product line could represent a new chapter in human–machine interaction.

Elon Musk says the tech will change lives

Musk believes Neuralink’s technology could become one of the most transformative innovations of the century. In response to patient updates like Audrey Crews’, Musk posted, “She is controlling her computer just by thinking. Most people don’t realize this is possible.”

His long-standing goal is to keep humans competitive in the age of AI by merging our brains with machines. Whether it’s restoring lost function or boosting healthy minds, Musk says this is only the beginning.

Neuralink’s software adapts over time

A key strength of Neuralink’s BCI is its software’s ability to adapt even when the hardware faces issues. In cases like Noland Arbaugh’s, where some electrode threads detached, engineers quickly updated the software to recalibrate signal reading.

This adaptability ensures that the chip can continue functioning even when conditions change. It also suggests that future updates could significantly enhance the chip’s capabilities without requiring a second surgery, a massive patient benefit.

Neuralink is not alone in the brain chip race

Several other companies are racing to bring BCIs to market. Apple is reportedly working with biotech company Synchron to develop brain-controlled device interfaces.

Meanwhile, startups like Blackrock Neurotech and Paradromics are advancing their implants for medical and commercial use.

While Neuralink gets the spotlight, the broader field of brain-computer technology is heating up, and competition may accelerate innovation across the board.

Want to see how high the stakes are in the brain-tech race? Even Elon’s xAI isn’t immune to slip-ups like a leaked API key tied to a government-linked DOGE staffer.

The UK trial may shape Neuralink’s future

Success in the UK trial could mark a turning point for Neuralink. Positive results may validate the tech in a primary healthcare system and encourage broader European adoption.

It would also help build public trust in brain-computer interfaces and cement Neuralink’s role as a pioneer.

For the seven British participants, it’s a chance to make history. For Neuralink, it’s a stepping stone to the future Musk has been promising for nearly a decade.

Curious how Musk’s other AI ventures are faring in Europe? Grok is already drawing fire this time over hate speech complaints in Poland.

What do you think about Elon Musk’s new brain chip? Testing will start soon. Please share your thoughts and drop a comment.

Read More From This Brand:

• Inside Elon Musk’s Plan to Revolutionize Supercomputing
• Could Trump keep Elon Musk’s xAI from winning federal work?
• Elon Musk introduces Baby Grok AI chatbot to help kids learn more effectively

Don’t forget to follow us for more exclusive content on MSN.

If you liked this story, you’ll LOVE our FREE emails. Join today and be the first to get stories like this one.

This slideshow was made with AI assistance and human editing.